<h4>Background</h4>Methylthioadenosine phosphorylase (MTAP) loss co-occurs with actionable genomic alterations in non-small cell lung cancer (NSCLC) and creates vulnerability to protein arginine methyltransferase 5 (PRMT5) inhibition. The gene discussed is MTAP; the disease is non-small cell lung carcinoma.